Scholarlink

<p>Pathological neovascularization and vascular leakage are central drivers of many sight-threatening diseases. While strategies targeting vascular endothelial growth factor (VEGF) have improved clinical outcomes, many patients do not benefit from the treatment, highlighting the need for alternative therapeutic strategies. Two independent vitreous proteomics studies in patients with proliferative diabetic retinopathy (PDR) reveal a significant reduction in Frizzled-related Protein (FRZB), a finding recapitulated in preclinical models of ocular angiogenesis. Here, we show that loss of <i>Frzb</i> exacerbates ocular angiogenesis, whereas therapeutic delivery of Fc-recombinant FRZB or its netrin-related motif (NTR) robustly suppresses and reverses ocular angiogenesis across various preclinical models. Fc-NTR acts additively with Aflibercept, supporting its potential as a combination therapy. Mechanistically, FRZB binds Caveolin-1 (CAV1), inhibits its phosphorylation at Tyr42, promotes retention of the TGFβ receptor ALK5, and enhances Smad2/3 signalling. These findings define FRZB as a potent suppressor of ocular angiogenesis and establish a promising therapeutic avenue.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Ching-Jou Chen,
  • Lei Zhou,
  • Han-Tang Chen,
  • Veluchamy Amutha Barathi,
  • Beiying Qiu,
  • Asfa Alli-Shaik,
  • Rui Ning Chia,
  • Seok Ting Lim,
  • Chaemin Joo,
  • Ning Cheung,
  • Choi Mun Chan,
  • Siew Kwan Koh,
  • Alison Tan,
  • Ravi Kumar Verma,
  • Hao Fan,
  • Weihua Song,
  • David Virshup,
  • Jayantha Gunaratne,
  • Tien Yin Wong,
  • Gemmy Chui Ming Cheung,
  • Wanjin Hong,
  • Xiaomeng Wang

摘要

Pathological neovascularization and vascular leakage are central drivers of many sight-threatening diseases. While strategies targeting vascular endothelial growth factor (VEGF) have improved clinical outcomes, many patients do not benefit from the treatment, highlighting the need for alternative therapeutic strategies. Two independent vitreous proteomics studies in patients with proliferative diabetic retinopathy (PDR) reveal a significant reduction in Frizzled-related Protein (FRZB), a finding recapitulated in preclinical models of ocular angiogenesis. Here, we show that loss of Frzb exacerbates ocular angiogenesis, whereas therapeutic delivery of Fc-recombinant FRZB or its netrin-related motif (NTR) robustly suppresses and reverses ocular angiogenesis across various preclinical models. Fc-NTR acts additively with Aflibercept, supporting its potential as a combination therapy. Mechanistically, FRZB binds Caveolin-1 (CAV1), inhibits its phosphorylation at Tyr42, promotes retention of the TGFβ receptor ALK5, and enhances Smad2/3 signalling. These findings define FRZB as a potent suppressor of ocular angiogenesis and establish a promising therapeutic avenue.